Oramed Pharmaceuticals ROA 2025

Oramed Pharmaceuticals Aktienanalyse

What does Oramed Pharmaceuticals do?

Oramed Pharmaceuticals Inc is an innovative biotech company headquartered in Jerusalem, Israel. The company was founded in 2006 by Nadav Kidron and specializes in the development of oral forms of protein-based therapeutics. The idea behind Oramed Pharmaceuticals was to revolutionize the way proteins are administered. Typically, protein-based drugs like insulin need to be administered in injectable form, which can be unpleasant and painful for many patients. Oramed Pharmaceuticals set out to find a solution to this problem. The company has developed a technology called ORMD-0801, which allows for the oral administration of insulin. The active ingredient is protected by a special capsule that monitors the pH level in the stomach. Once the capsule reaches the small intestine, the active ingredient is released and can be absorbed by the body. Oramed Pharmaceuticals aims to improve the treatment of diabetes. With the oral form of insulin, patients can take their medication much easier and more conveniently. This can help improve treatment and increase patients' quality of life. In addition to the development of ORMD-0801, Oramed Pharmaceuticals is also working on developing oral forms of other protein-based therapeutics. The company has filed a variety of patents for technologies and therapies and actively collaborates with other companies and research institutions. Oramed Pharmaceuticals has two main divisions: the development department and the commercialization department. The development department is responsible for the research and development of new therapies, while the commercialization department is responsible for sales and marketing of the products. Oramed Pharmaceuticals' business model is focused on developing innovative therapies and bringing them to market. The company works closely with other companies and research institutions to advance the development of new therapies. Oramed Pharmaceuticals is currently working on several projects to develop additional orally administered protein-based therapeutics. In addition to insulin, the company is also working on proteins that can be used in the treatment of other diseases such as osteoporosis and Parkinson's. The products of Oramed Pharmaceuticals are of great importance to both patients and the medical community. The oral forms of protein-based therapeutics can help make the treatment of diabetes and other diseases much easier and more convenient. This can help increase patient satisfaction and improve compliance. In recent years, Oramed Pharmaceuticals has received several awards and accolades for its innovative products. The company continues to work on developing new therapies and changing the way medication is administered. Oramed Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Oramed Pharmaceuticals's Return on Assets (ROA)

Oramed Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Oramed Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Oramed Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Oramed Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Oramed Pharmaceuticals stock

What is the Return on Assets (ROA) of Oramed Pharmaceuticals this year?

The Return on Assets (ROA) of Oramed Pharmaceuticals is 0.03 undefined this year.

What was the ROA of Oramed Pharmaceuticals compared to the previous year?

The ROA of Oramed Pharmaceuticals has increased by -111.07% compared to the previous year.

What consequences do high ROA have for investors of Oramed Pharmaceuticals?

A high ROA is advantageous for investors of Oramed Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Oramed Pharmaceuticals?

A low ROA can be unfavorable for investors of Oramed Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Oramed Pharmaceuticals affect the company?

An increase in ROA of Oramed Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Oramed Pharmaceuticals impact the company?

A reduction in the ROA of Oramed Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Oramed Pharmaceuticals?

Some factors that can influence the ROA of Oramed Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Oramed Pharmaceuticals important for investors?

The ROA of Oramed Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Oramed Pharmaceuticals take to improve ROA?

To improve ROA, Oramed Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Oramed Pharmaceuticals pay?

Over the past 12 months, Oramed Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oramed Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Oramed Pharmaceuticals?

The current dividend yield of Oramed Pharmaceuticals is .

When does Oramed Pharmaceuticals pay dividends?

Oramed Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oramed Pharmaceuticals?

Oramed Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Oramed Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oramed Pharmaceuticals located?

Oramed Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oramed Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oramed Pharmaceuticals from 1/25/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/25/2025.

When did Oramed Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/25/2025.

What was the dividend of Oramed Pharmaceuticals in the year 2024?

In the year 2024, Oramed Pharmaceuticals distributed 0 USD as dividends.

In which currency does Oramed Pharmaceuticals pay out the dividend?

The dividends of Oramed Pharmaceuticals are distributed in USD.